Latest News for: xeri

Edit

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent ...

Norfolk Daily News 12 Jun 2026
Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris’ commitment to ... .
Edit

XERIS BIOPHARMA ANNOUNCES PRIVATE EXCHANGE OF CONVERTIBLE NOTES (Form 8-K) (Xeris Biopharma Holdings Inc)

Public Technologies 11 Jun 2026
) XERIS BIOPHARMA ANNOUNCES PRIVATE EXCHANGE OF CONVERTIBLE NOTES ... CHICAGO, IL; June 11, 2026 - Xeris Biopharma Holdings, Inc ... Following the closing of the exchanges, Xeris will have $10.5 million in aggregate principal amount of the Notes outstanding.
Edit

Xeris Biopharma Announces Private Exchange of Convertible Notes

Business Wire 11 Jun 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc ... Pursuant to the exchange agreements, Xeris ...
Edit

The AMF has decided to withdraw the authorisation of the asset management company Xerys Invest (AMF - Financial Markets Authority of the French Republic)

Public Technologies 10 Jun 2026
... (AMF) has decided to withdraw the authorisation of the asset management company Xerys Invest in view of its situation.
Edit

Proxy Results (Form 8-K) (Xeris Biopharma Holdings Inc)

Public Technologies 05 Jun 2026
) Item 5.07 Submission of Matters to a Vote of Security Holders. On June 4, 2026, Xeris Biopharma Holdings, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") ... Xeris Biopharma Holdings Inc.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Xeris Biopharma Holdings Inc)

Public Technologies 05 Jun 2026
) FORM 4. Check this box if no longer subject to Section 16 ... See Instruction 1(b) ... 2 ... Xeris Biopharma Holdings, Inc ... C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300 3 ... C/O XERIS BIOPHARMA HOLDINGS, INC ... Xeris Biopharma Holdings Inc.
Edit

Notice of Proposed Sale of Securities (Form 144) (Xeris Biopharma Holdings Inc)

Public Technologies 04 Jun 2026
) ... You can access the original document here ... Disclaimer. Xeris Biopharma Holdings Inc.
Edit

Xeris Biopharma: Q1 Earnings Snapshot

Clinton Herald 08 May 2026
CHICAGO (AP) — CHICAGO (AP) — Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported first-quarter net income of $2.2 million ... .
Edit

Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) (Xeris Biopharma Holdings Inc)

Public Technologies 08 May 2026
along with its subsidiaries, is referenced herein as the "Company," "Xeris," "Xeris Biopharma," "we" or "our." Throughout this document, unless ...
Edit

Xeris Biopharma Reports First Quarter 2026 Financial Results

Business Wire 07 May 2026
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ... .
Edit

XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS (Form 8-K) (Xeris Biopharma Holdings Inc)

Public Technologies 07 May 2026
) XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ... CHICAGO, IL; May 7, 2026 - Xeris Biopharma Holdings, Inc ... Xeris will host a conference call and webcast at 8.30 a.m ... Xeris Biopharma Holdings Inc.
Edit

2026 Proxy Statement (Xeris Biopharma Holdings Inc)

Public Technologies 24 Apr 2026
Based on the reviews and discussions referred to above, the Audit Committee recommended to the board of directors that the audited consolidated financial statements of Xeris be included in Xeris' ...
Edit

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

Business Wire 23 Apr 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq ... financial markets on Thursday, May 7, 2026.
Edit

Annual Report (Form ARS) (Xeris Biopharma Holdings Inc)

Public Technologies 23 Apr 2026
) ... You can access the original document here ... Disclaimer. Xeris Biopharma Holdings Inc.
Edit

Additional Proxy Soliciting Materials (Form DEFA14A) (Xeris Biopharma Holdings Inc)

Public Technologies 23 Apr 2026
). UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549. SCHEDULE 14A INFORMATION. Proxy Statement Pursuant to Section 14(a) of the. Securities Exchange Act of 1934 ... ) ... ¨ ... ¨ ... ¨ ... þ ... ¨ ... XERIS BIOPHARMA HOLDINGS, INC ... Xeris Biopharma Holdings Inc.

Article Search

tools
×
×
×
×